{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:10:09Z","timestamp":1769109009772,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rivaroxaban has been recently introduced for the management of non-valvular intra-cardiac thrombosis with variable results. We aimed to compare the results of the off-label use of rivaroxaban versus warfarin in the management of patients with left ventricle (LV) thrombus. This research is a retrospective study conducted on 63 patients who had LV thrombus from January to December 2016. We compared patients treated with warfarin (<jats:italic>n<\/jats:italic>=35) to patients who had rivaroxaban (<jats:italic>n<\/jats:italic>=28), and study outcomes were time to thrombus resolution, bleeding, stroke, and mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median duration of treatment was 9.5 (25th-75th percentiles: 6-32.5) months for rivaroxaban and 14 (3-41) months for warfarin. Thrombus resolution occurred in 24 patients in the warfarin group (68.6%) and 20 patients in the rivaroxaban group (71.4%). The median time to resolution in the warfarin group was 9 (4-20) months and 3 (2-11.5) months in the rivaroxaban group. Thrombus resolution was significantly faster in patients on rivaroxaban (<jats:italic>p<\/jats:italic>= 0.019). Predictors of thrombus resolution were thrombus surface area (HR: 1.21; CI 95% (1.0-1.46); <jats:italic>p<\/jats:italic>= .048) and the use of rivaroxaban (HR: 1.92; CI 95% (1.01-3.65); <jats:italic>p<\/jats:italic>= 0.048). There was no difference in stroke, bleeding, and mortality between both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Rivaroxaban was as effective and safe as warfarin in managing patients with left ventricle thrombus. Larger randomized clinical trials are recommended to confirm our findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-021-00164-7","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T11:43:03Z","timestamp":1620042183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Rivaroxaban versus warfarin for the management of left ventricle thrombus"],"prefix":"10.1186","volume":"73","author":[{"given":"Monirah A.","family":"Albabtain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"Alhebaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Al-Yafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatim","family":"Kheirallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haneen","family":"Alghosoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-7287","authenticated-orcid":false,"given":"Amr A.","family":"Arafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alfagih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"164_CR1","doi-asserted-by":"crossref","unstructured":"Makrides CA (2016) Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. BMJ Case Rep. 2016","DOI":"10.1136\/bcr-2016-217843"},{"key":"164_CR2","doi-asserted-by":"crossref","unstructured":"Bahmaid RA, Ammar S, Al-Subaie S, Soofi MA, Mhish H, Yahia MA. Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus-a case series and literature review. Vol. 8, JRSM cardiovascular disease. England; 2019. p. 2048004019839548.","DOI":"10.1177\/2048004019839548"},{"key":"164_CR3","unstructured":"Degheim G, Berry A, Zughaib M. Off label use of direct oral anticoagulants for left ventricular thrombus. Is it appropriate? Vol. 7, American journal of cardiovascular disease. United States; 2017. p. 98\u2013101."},{"key":"164_CR4","doi-asserted-by":"publisher","unstructured":"McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi Jr JL, Bhatt DL, McEvoy JW. Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment. JAMA Cardiol [Internet]. 2018 1;3(7):642\u20139. Available from: https:\/\/doi.org\/10.1001\/jamacardio.2018.1086","DOI":"10.1001\/jamacardio.2018.1086"},{"key":"164_CR5","unstructured":"Bhatnagar UB, Rezkalla J, Sethi P, Stys A. Successful resolution of a large left ventricular thrombus with rivaroxaban therapy after acute myocardial infarction. Vol. 71, South Dakota medicine: the journal of the South Dakota State Medical Association. United States; 2018. p. 62\u20133."},{"issue":"1","key":"164_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.14744\/AnatolJCardiol.2018.48313","volume":"21","author":"M Abdelnaby","year":"2019","unstructured":"Abdelnaby M, Almaghraby A, Abdelkarim O, Saleh Y, Hammad B, Badran H (2019) The role of rivaroxaban in left ventricular thrombi. Anatol J Cardiol. 21(1):47\u201350. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2018.48313","journal-title":"Anatol J Cardiol."},{"key":"164_CR7","doi-asserted-by":"publisher","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation [Internet]. 2011 123(23):2736\u201347. Available from: https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"164_CR8","doi-asserted-by":"publisher","first-page":"814524","DOI":"10.1155\/2014\/814524","volume":"2014","author":"K Nakasuka","year":"2014","unstructured":"Nakasuka K, Ito S, Noda T, Hasuo T, Sekimoto S, Ohmori H et al (2014) Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep Med. 2014:814524","journal-title":"Case Rep Med."},{"key":"164_CR9","doi-asserted-by":"crossref","unstructured":"Esteve-Pastor MA, Orenes-Pinero E, Roldan V, Lacunza-Ruiz J, Valdes M, Marin F. Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. Vol. 25, Cardiology journal. Poland; 2018. p. 151\u20134.","DOI":"10.5603\/CJ.2018.0014"},{"issue":"1","key":"164_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11239-018-1656-8","volume":"46","author":"AS-T Leow","year":"2018","unstructured":"Leow AS-T, Sia C-H, Tan BY-Q, Loh JP-Y (2018) A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus. J Thromb Thrombolysis. 46(1):68\u201373. https:\/\/doi.org\/10.1007\/s11239-018-1656-8","journal-title":"J Thromb Thrombolysis."},{"key":"164_CR11","doi-asserted-by":"crossref","unstructured":"Gaznabi S, Abugroun A, Mahbub H, Campos E. Successful resolution of a large left atrial and left atrial appendage thrombus with rivaroxaban. Vol. 2019, Case reports in cardiology. United States; 2019. p. 6076923.","DOI":"10.1155\/2019\/6076923"},{"issue":"2","key":"164_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s11239-019-01876-z","volume":"48","author":"H-H Ke","year":"2019","unstructured":"Ke H-H, He Y, Lv X-W, Zhang E-H, Wei Z, Li J-Y (2019 Aug) Efficacy and safety of rivaroxaban on the resolution of left atrial\/left atrial appendage thrombus in nonvalvular atrial fibrillation patients. J Thromb Thrombolysis. 48(2):270\u2013276. https:\/\/doi.org\/10.1007\/s11239-019-01876-z","journal-title":"J Thromb Thrombolysis."},{"key":"164_CR13","doi-asserted-by":"publisher","unstructured":"Robinson AA, Trankle CR, Eubanks G, Schumann C, Thompson P, Wallace RL, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol [Internet]. 2020 5(6):685\u2013692. Available from: https:\/\/doi.org\/10.1001\/jamacardio.2020.0652","DOI":"10.1001\/jamacardio.2020.0652"},{"key":"164_CR14","doi-asserted-by":"crossref","unstructured":"Jones DA, Wright P, Alizadeh MA, Fhadil S, Rathod KS, Guttmann O, et al. The use of novel oral anti-coagulant\u2019s (NOAC) compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction (AMI). Eur Hear journal Cardiovasc Pharmacother. 2020","DOI":"10.1093\/ehjcvp\/pvaa096"},{"key":"164_CR15","doi-asserted-by":"crossref","unstructured":"Bass ME, Kiser TH, Page RL 2nd, McIlvennan CK, Allen LA, Wright G, et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021","DOI":"10.1007\/s11239-020-02371-6"},{"issue":"3","key":"164_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.amjcard.2019.05.009","volume":"124","author":"AM Fleddermann","year":"2019","unstructured":"Fleddermann AM, Hayes CH, Magalski A, Main ML (2019) Efficacy of direct acting oral anticoagulants in treatment of left ventricular thrombus. Am J Cardiol. 124(3):367\u2013372. https:\/\/doi.org\/10.1016\/j.amjcard.2019.05.009","journal-title":"Am J Cardiol."},{"issue":"11","key":"164_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.15537\/smj.2020.11.25456","volume":"41","author":"MA Albabtain","year":"2020","unstructured":"Albabtain MA, Alharthi MM, Dagriri K, Arafat AA, Ayrout E, Alhebaishi Y, AlFagih A (2020) Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J. 41(11):1245\u20131251. https:\/\/doi.org\/10.15537\/smj.2020.11.25456","journal-title":"Saudi Med J."},{"issue":"3","key":"164_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/eurheartj\/ehx551","volume":"39","author":"N Maniwa","year":"2018","unstructured":"Maniwa N, Fujino M, Nakai M, Nishimura K, Miyamoto Y, Kataoka Y, Asaumi Y, Tahara Y, Nakanishi M, Anzai T, Kusano K, Akasaka T, Goto Y, Noguchi T, Yasuda S (2018) Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. Eur Heart J. 39(3):201\u2013208. https:\/\/doi.org\/10.1093\/eurheartj\/ehx551","journal-title":"Eur Heart J."},{"key":"164_CR19","doi-asserted-by":"publisher","unstructured":"Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, et al. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J [Internet]. 2018 39(13):1078\u20131085. Available from: https:\/\/doi.org\/10.1093\/eurheartj\/ehy013","DOI":"10.1093\/eurheartj\/ehy013"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-021-00164-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T07:17:01Z","timestamp":1626851821000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-021-00164-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1186\/s43044-021-00164-7","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Prince Sultan Medical City (Reference number E16012) in 2016. The study is retrospective and consent to participate was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}